Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
Status:
Completed
Trial end date:
2021-05-28
Target enrollment:
Participant gender:
Summary
This trial is aimed to investigate the safety, tolerability, PK and PD of multiple
subcutaneous injections of IBI362 in Chinese patients with type 2 diabetes who have poor
glycemic control after lifestyle or metformin intervention